Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2010

View Archived Issues

PAF-R is potential target to treat psoriasis

RAAM-DHF trial finds eplerenone may benefit patients with diastolic heart failure

Lundbeck and Argenta disclose promising preclinical data on MCH1 receptor antagonists

Enoxaparin yields superior net clinical benefit to UFH in subjects undergoing PCI for STEMI

Almirall describes pre-candidate agents for multiple sclerosis

Consistent stability data for Adventrx's ANX-530 to support NDA submission

Abbott responds to FDA advisory committee vote regarding sibutramine

DHEAS levels in plasma identified as putative biomarker for fibromyalgia

Domain Therapeutics describes new adenosine A2A and A3 receptor antagonists

CytoGenix presents preclinical data on DNA vaccine CYDBA-507 for avian flu

Atox Bio doses first participant in phase I AB-103 study

Phase II data reported on STX-209 in autism spectrum disorders

Resverlogix modifies phase II ASSURE trial of RVX-208

SK Holdings presents new inhibitors of MAO-B

Derma Sciences to complete enrollment in phase II trial of DSC-127

TransPharma completes phase Ia ViaDerm-GLP1 agonist trial

Banyu Pharma identifies new inhibitors of wee1-like protein kinase

GSK and Genmab to refocus ofatumumab development program

Immune Targeting Systems begins phase I trial of FP-01

Orexo grants NewBridge rights to market Abstral in Middle East and Africa

Eisai describes new inhibitors of beta-amyloid peptide production

Lonza to manufacture five monoclonal antibodies for GSK under new agreement

Enrollment of first cohort complete in phase I trial of PV-10 for liver cancer

Phase I trial data reported for Pluristem's PLX-PAD in critical limb ischemia

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...